1Q23 Business Results

HerzumaⓇ ✓ Started direct sales since 2H22 in Europe, recovered the revenue by winning bids in Türkiye and Hungary ✓ M/S in Japan exceeded the original's and continues to increase; Continuous winning from the tender in LATAM M/S of HerzumaⓇ in Europe 4% 0% 18% 19% 16% 15% 13% 13% 13% M/S of HerzumaⓇ in Japan 23% 14% 19.08 approval of 3-weekly regimen 12% 25% 50% 51% 53% 54% 55% 57% 46% 44% 39% 35% 59% 2% 0% 18.1Q 2Q 3Q 4Q 19.1Q 2Q 3Q 4Q 20.1Q 2Q Herzuma® 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q -HerceptinⓇ 3Q 4Q 19.2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q 3Q 4Q HerzumaⓇ Herceptin® F Biosimilar ............G Biosimilar E Biosimilar Note: The market share is based on volume Source: IQVIA Note: The market share is based on volume Source: IQVIA Investor Relations 2023 10 1Q23 Business Results Key Products Plan & Vision Appendix

View entire presentation